Back to ITCI Stock Lookup
Pages: 1 2 »» Last Page

Intra-Cellular Therapies (ITCI) – Globe Newswire

Jun 7, 2021 08:00 AM CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
May 26, 2021 08:00 AM Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 10, 2021 07:30 AM Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021 08:00 AM Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 4, 2021 08:00 AM Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
May 3, 2021 07:30 AM Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
Apr 22, 2021 07:30 AM Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting
Apr 20, 2021 07:00 AM Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting
Apr 12, 2021 07:30 AM Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annua
Feb 25, 2021 07:30 AM Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update
Feb 24, 2021 07:30 AM Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284
Feb 22, 2021 08:00 AM Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
Feb 19, 2021 08:00 AM Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference
Feb 17, 2021 08:00 AM Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast
Jan 21, 2021 08:00 AM CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research
Jan 5, 2021 08:00 AM Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 29, 2020 08:00 AM Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Tre
Dec 9, 2020 08:00 AM Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology
Nov 30, 2020 08:00 AM Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Nov 9, 2020 07:30 AM Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 4, 2020 08:00 AM Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
Oct 1, 2020 04:30 PM Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
Sep 15, 2020 08:00 AM Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Sep 14, 2020 08:00 AM Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference
Sep 10, 2020 08:30 PM Intra-Cellular Therapies Prices Public Offering of Common Stock
Sep 9, 2020 04:01 PM Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Sep 9, 2020 07:00 AM Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression
Aug 10, 2020 07:30 AM Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Aug 4, 2020 08:00 AM Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast
Jun 29, 2020 08:00 AM Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure
May 14, 2020 08:00 AM Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
May 13, 2020 04:15 PM Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders
May 7, 2020 07:30 AM Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
Apr 29, 2020 08:00 AM Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast
Apr 16, 2020 04:45 PM Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 2, 2020 08:00 AM Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
Mar 23, 2020 07:30 AM Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
Mar 2, 2020 07:30 AM Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Feb 24, 2020 08:00 AM Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast
Feb 21, 2020 04:15 PM Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 20, 2020 05:00 PM Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry
Feb 18, 2020 08:00 AM Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference
Jan 7, 2020 09:47 PM Intra-Cellular Therapies Prices Public Offering of Common Stock
Jan 6, 2020 04:06 PM Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Jan 2, 2020 08:00 AM Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 23, 2019 06:59 AM FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
Dec 12, 2019 07:30 AM Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology
Dec 4, 2019 08:00 AM Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology
Nov 5, 2019 07:30 AM Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Oct 29, 2019 08:00 AM Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast
Pages: 1 2 »» Last Page

Back to ITCI Stock Lookup